NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisal guidance no.'s 96, 153, 154 and 173; Entecavir, telbivudine, tenofovir disoproxil fumarate, adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Bristol-Myers Squibb Pharmaceuticals (entecavir)	Board of Community Health Councils in Wales
Gilead Sciences (adefovir dipivoxil)	British National Formulary
Novartis Pharmaceuticals UK	Care Quality Commission
(telbivudine)	Commissioning Support Appraisals
 Roche Products (peginterferon alfa- 	Service
2a)	Department of Health, Social Services
	and Public Safety for Northern Ireland
Patient/carer groups	Healthcare Improvement Scotland
Afiya Trust	 Medicines and Healthcare products
Alliance	Regulatory Agency
• AVERT	National Association of Primary Care
Black Health Agency	National Pharmacy Association
British Liver Trust	NHS Alliance
British Organ Donor Society (BODY)	NHS Commercial Medicines Unit
Chinese National Healthy Living	NHS Confederation
Centre	Public Health Wales NHS Trust
Compass UK	Scottish Medicines Consortium
Counsel and Care	
Drugs Action	Possible comparator manufacturer(s)
Drugscope	Glaxosmithkline (lamivudine)
Equalities National Council One Manage Handton	Merck Sharpe and Dohme (interferon
GMFA - The Gay Men's Health Charity	alfa-2b, peginterferon alfa-2b)
Literature Allierature	Relevant research groups
11	Centre for Sexual Health & HIV
Haemophilia SocietyHepatitis A –Z	Research
Hepatitis A – 2 Hepatitis B Foundation UK	Cochrane Hepato-Biliary Group
Muslim Council of Britain	Cochrane Infectious Diseases Group
Muslim Health Network	Foundation for Liver Research
NAM Publications	MRC Clinical Trials Unit
National AIDS Trust	National Institute of Health Research
Positively UK	Research Institute for the Care of Older

National Institute for Health and Clinical Excellence

NICE Technology Appraisal guidance no.'s 96, 153, 154 and 173; Entecavir, telbivudine, tenofovir disoproxil fumarate, adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B Issue date: tbc 2011 Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
 South Asian Health Foundation Specialised Healthcare Alliance Terrence Higgins Trust Transplant Support Network Youth Net Professional groups Association of Clinical Microbiologists Association of Nurses in Substance Abuse Association of Surgeons of Great Britain and Ireland British Association for Services to the Elderly British Association for Sexual Health and HIV British Geriatrics Society British HIV Association British Infection Association British Liver Nurses Forum British Society of Gastroenterology British Transplantation Society British Viral Hepatitis Group European Association for the Treatment of Addiction UK Haemophilia Nurses Association Health Protection Agency Hepatitis Nurse Specialist Forum Infection Control Nurses Association Medical Foundation for AIDS & Sexual Health Royal College of Anaesthetists Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society for General Microbiology United Kingdom Clinical Virology 	People Assessment Group Assessment Group tbc National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups tbc

Issue date: tbc 2011 Page 2 of 4

Consultees	Commentators (no right to submit or appeal)
Network United Kingdom Clinical Pharmacy Association United Kingdom Haemophilia Centre Doctors' Organisation	
Others Department of Health Heart of Birmingham Teaching Primary Care Trust NHS Blackburn with Darwen Teaching Care Trust Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: tbc 2011 Page 3 of 4

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, Care Quality Commission and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.